New drug combo shows promise for tough breast cancer in early trial
NCT ID NCT07197697
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study tests a new combination of drugs (iparomlimab and tuvonralimab with chemotherapy) given before surgery to 30 people with a common type of breast cancer called HR+/HER2-. The goal is to see if the treatment can eliminate all cancer cells in the breast and lymph nodes by the time of surgery. If successful, the drug combo may be studied further as a way to improve outcomes for patients with this type of breast cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.